IMATERO (Imatinib) – effectively inhibits the enzyme Bcr-Abl-tyrosine kinase at the cellular level. Imatinib selectively inhibits proliferation and induces apoptosis in Bcr-Abl-positive cell lines, as well as immature leukemia cells in chronic myeloid leukemia with positive Philadelphia chromosome (Ph +) and in acute lymphoblastic leukemia. Imatinib selectively inhibits Bcr-Abl-positive colonies derived from blood cells in patients with chronic myeloid leukemia
The drug has antitumor activity in monotherapy.
In addition, imatinib is a potent inhibitor of platelet growth factor (PDGF) and stem cell factor (SCF) c-Kit receptor tyrosine kinase, and inhibits cellular responses mediated by the above factors. In vitro, imatinib inhibits proliferation and induces apoptosis of stromal tumor cells of the gastrointestinal tract expressing Kit mutations.